Skip to main content

Table 4 Plasma lipids significantly (p < 0.05) associated with baseline eGFR. Effect size represents the magnitude and direction (+/−) of association between a given lipid and eGFR, estimated by linear regression, while controlling for the selected HALT covariates, age, sex, genotype, site of sample collection, and BMI

From: Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course

Lipid Effect Size (SD) p-value FDR q-value
Acylcarnitine(10:1) [M + H]+ −0.0424 (0.013) 0.0010 0.0737
Triglyceride(53:3) [M + K]+ −0.0516 (0.017) 0.0033 0.1024
Acylcarnitine(14:2) [M + H]+ −0.0303 (0.011) 0.0057 0.1024
Acylcarnitine(12:1) [M + H]+ −0.0350 (0.013) 0.0059 0.1024
Acylcarnitine(8:0) [M + H]+ −0.0291 (0.011) 0.0071 0.1024
Triglyceride(54:5) A [M + K]+ −0.0470 (0.020) 0.0199 0.2364
Phosphatidylcholine(28:0) [M + H]+ 0.0275 (0.012) 0.0229 0.2364
Phosphatidylcholine(38:7) [M + H]+ 0.0578 (0.028) 0.0397 0.2959
Triglyceride(59:3) [M + NH4]+ −0.0320 (0.015) 0.0399 0.2959
Diglyceride(32:0) [M + K]+ 0.0506 (0.025) 0.0409 0.2959
Phosphatidylcholine(30:0) [M + H]+ 0.0307 (0.015) 0.0477 0.3137